Maxion Therapeutics
PrivateLast Round
Series A
Mar 17, 2025
Total Funding Raised
$90.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Maxion Therapeutics is a biotechnology company that develops antibody-based KnotBody® drugs for ion channel and G protein-coupled receptor (GPCR)-driven diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Maxion Therapeutics Comparables
Compare Maxion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Confo Therapeutics | 86% | |
| Abilita Therapeutics | 84% | |
| AbbVie | 77% |
Maxion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 17, 2025 | ||||
| Grant | Apr 19, 2023 | ||||
| Seed | Feb 15, 2023 |
Key People
Founding team and executive leadership
Maxion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| BGF | Series A, Seed |
| British Patient Capital | Series A |
| Monograph Capital | Series A, Seed |
| General Catalyst | Series A |
| Innovate UK | Grant |
| British Patient Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 65% MoM, reaching 1.8K.
- Oct 1, 2025
Joel Edwards appointed as new Chief Business Officer.
Maxion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Maxion Therapeutics's valuation, stock price, and market status.
Is Maxion Therapeutics a public or private company?
Maxion Therapeutics is a private company.
What is the current stock price of Maxion Therapeutics?
Maxion Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Maxion Therapeutics worth (valuation)?
Valuation information for Maxion Therapeutics is not publicly available.
Can I buy Maxion Therapeutics stock?
Maxion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Maxion Therapeutics's last funding round?
Maxion Therapeutics's most recent funding round was Series A on March 17, 2025.
Who are the main investors in Maxion Therapeutics?
Key investors in Maxion Therapeutics include General Catalyst, LifeArc Ventures.
Will Maxion Therapeutics IPO soon?
No public IPO plans have been announced for Maxion Therapeutics.
How can I track Maxion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Maxion Therapeutics's secondary market activity and sign up for updates.